Advanced Nanomaterials for Preparedness Against (Re‐)Emerging Viral Diseases

Abstract

While the coronavirus disease (COVID‐19) accounts for the current global pandemic, the emergence of other unknown pathogens, named “Disease X,” remains a serious concern in the future. Emerging or re‐emerging pathogens continue to pose significant challenges to global public health. In response, the scientific community has been urged to create advanced platform technologies to meet the ever‐increasing needs presented by these devastating diseases with pandemic potential. This review aims to bring new insights to allow for the application of advanced nanomaterials in future diagnostics, vaccines, and antiviral therapies, thereby addressing the challenges associated with the current preparedness strategies in clinical settings against viruses. The application of nanomaterials has advanced medicine and provided cutting‐edge solutions for unmet needs. Herein, an overview of the currently available nanotechnologies is presented, highlighting the significant features that enable them to control infectious diseases, and identifying the challenges that remain to be addressed for the commercial production of nano‐based products is presented. Finally, to conclude, the development of a nanomaterial‐based system using a “One Health” approach is suggested. This strategy would require a transdisciplinary collaboration and communication between all stakeholders throughout the entire process spanning across research and development, as well as the preclinical, clinical, and manufacturing phases.

A Membrane‐Targeting Photosensitizer with Aggregation‐Induced Emission Characteristics for Highly Efficient Photodynamic Combat of Human Coronaviruses

“…[ 9 ] Therefore, developing efficient surfaces and coatings materials to minimize the presence of active viral pathogens and prevent the spread of infectious pathogens in a variety of public places, such as hospitals, public transportations, and schools, are highly desirable. [ 10 , 11 , 12 ]…”

An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times

“…The delivery of mRNA in non-toxic carriers was the main challenge for guaranteeing its effect, because mRNA is a very labile and easily degradable molecule, particularly given the widespread presence of RNases [103]. Cutting-edge nanotechnology research suggested the use of lipid nanoparticles (LNPs) as formulations that facilitate the release of mRNA into cells from endosomes [104,105]. The design for BNT162b2 and mRNA-1273 included low copy numbers (1-10) of mRNA bathed in aqueous solution and attached to the LNP, which consists of a bilayer lipidic vesicle with polyethylene glycol (PEG) on the surface and cholesterol, phospholipids, and an ionizable lipid in the structure.…”

Application of Nanomaterials as an Advanced Strategy for the Diagnosis, Prevention, and Treatment of Viral Diseases

“…The WHO Emergency Use Listing for combating the COVID-19 pandemic includes vaccines that incorporate a delivery system based on NPs, such as lipid NPs (LNPs) (Moderna, MA, US and Pfizer-BioNTech, NY, US) and adenovirus viral vectors (Janssen, NJ, US and Astra-Zeneca, UK) (Figure 2). Delivery systems formulated with NPs are being used in next-generation vaccines for effectively delivering antigens and/or intrinsic immunostimulants [93][94][95][96][97]. These vaccines are being engineered not only for the prevention of emerging infectious diseases, but also for treating chronic diseases, such as diseases caused by hepatitis C infections [98,99], human immunodeficiency virus (HIV) infections [100,101], herpes [102], and cancer.…”